Clinical usefulness of mepolizumab in severe eosinophilic asthma

Francesco Menzella, Mirco Lusuardi, Gloria Montanari, Carla Galeone, Nicola Facciolongo, Luigi Zucchi

Research output: Contribution to journalReview article

16 Citations (Scopus)

Abstract

Asthma is a chronic inflammatory disorder of the airways with variable clinical severity from very mild and occasional symptoms to recurrent critical exacerbations, at risk of fatal or near-fatal outcome, in a small percentage of patients. Within the different inflammatory cascades involved in asthma, eosinophils play a central role in the pathogenesis and largely influence disease severity. Interleukin-5 (IL-5) is the main cytokine controlling eosinophil activity and proliferation at the site of inflammation. Mepolizumab was the first biological humanized anti-IL-5 monoclonal antibody tested in randomized clinical trials on eosinophilic asthma and other eosinophilic diseases. On the basis of several positive clinical efficacy data, it has recently been approved by the US Food and Drug Administration for the treatment of severe eosinophilic asthma. Unfortunately, high costs are at present a critical issue. Future studies will probably help in the correct selection of a potential “responder phenotype”, allowing the prescription of this promising therapy to appropriate patients and best define cost-effectiveness issues.

Original languageEnglish
Pages (from-to)907-916
Number of pages10
JournalTherapeutics and Clinical Risk Management
Volume12
DOIs
Publication statusPublished - Jun 8 2016

Fingerprint

Interleukin-5
Asthma
Disease
Monoclonal antibodies
Cost effectiveness
costs
Eosinophils
proliferation
medication
Monoclonal Antibodies
Cytokines
Fatal Outcome
present
United States Food and Drug Administration
Cost-Benefit Analysis
Prescriptions
Costs
Randomized Controlled Trials
Inflammation
Phenotype

Keywords

  • Asthma
  • Biomarkers
  • Effectiveness
  • IL-5
  • Mepolizumab
  • Phenotype

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Medicine(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Safety Research
  • Chemical Health and Safety

Cite this

Menzella, F., Lusuardi, M., Montanari, G., Galeone, C., Facciolongo, N., & Zucchi, L. (2016). Clinical usefulness of mepolizumab in severe eosinophilic asthma. Therapeutics and Clinical Risk Management, 12, 907-916. https://doi.org/10.2147/TCRM.S86299

Clinical usefulness of mepolizumab in severe eosinophilic asthma. / Menzella, Francesco; Lusuardi, Mirco; Montanari, Gloria; Galeone, Carla; Facciolongo, Nicola; Zucchi, Luigi.

In: Therapeutics and Clinical Risk Management, Vol. 12, 08.06.2016, p. 907-916.

Research output: Contribution to journalReview article

Menzella, F, Lusuardi, M, Montanari, G, Galeone, C, Facciolongo, N & Zucchi, L 2016, 'Clinical usefulness of mepolizumab in severe eosinophilic asthma', Therapeutics and Clinical Risk Management, vol. 12, pp. 907-916. https://doi.org/10.2147/TCRM.S86299
Menzella F, Lusuardi M, Montanari G, Galeone C, Facciolongo N, Zucchi L. Clinical usefulness of mepolizumab in severe eosinophilic asthma. Therapeutics and Clinical Risk Management. 2016 Jun 8;12:907-916. https://doi.org/10.2147/TCRM.S86299
Menzella, Francesco ; Lusuardi, Mirco ; Montanari, Gloria ; Galeone, Carla ; Facciolongo, Nicola ; Zucchi, Luigi. / Clinical usefulness of mepolizumab in severe eosinophilic asthma. In: Therapeutics and Clinical Risk Management. 2016 ; Vol. 12. pp. 907-916.
@article{4d7cbde5fd654de396b6d3dd11d90cb8,
title = "Clinical usefulness of mepolizumab in severe eosinophilic asthma",
abstract = "Asthma is a chronic inflammatory disorder of the airways with variable clinical severity from very mild and occasional symptoms to recurrent critical exacerbations, at risk of fatal or near-fatal outcome, in a small percentage of patients. Within the different inflammatory cascades involved in asthma, eosinophils play a central role in the pathogenesis and largely influence disease severity. Interleukin-5 (IL-5) is the main cytokine controlling eosinophil activity and proliferation at the site of inflammation. Mepolizumab was the first biological humanized anti-IL-5 monoclonal antibody tested in randomized clinical trials on eosinophilic asthma and other eosinophilic diseases. On the basis of several positive clinical efficacy data, it has recently been approved by the US Food and Drug Administration for the treatment of severe eosinophilic asthma. Unfortunately, high costs are at present a critical issue. Future studies will probably help in the correct selection of a potential “responder phenotype”, allowing the prescription of this promising therapy to appropriate patients and best define cost-effectiveness issues.",
keywords = "Asthma, Biomarkers, Effectiveness, IL-5, Mepolizumab, Phenotype",
author = "Francesco Menzella and Mirco Lusuardi and Gloria Montanari and Carla Galeone and Nicola Facciolongo and Luigi Zucchi",
year = "2016",
month = "6",
day = "8",
doi = "10.2147/TCRM.S86299",
language = "English",
volume = "12",
pages = "907--916",
journal = "Therapeutics and Clinical Risk Management",
issn = "1176-6336",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Clinical usefulness of mepolizumab in severe eosinophilic asthma

AU - Menzella, Francesco

AU - Lusuardi, Mirco

AU - Montanari, Gloria

AU - Galeone, Carla

AU - Facciolongo, Nicola

AU - Zucchi, Luigi

PY - 2016/6/8

Y1 - 2016/6/8

N2 - Asthma is a chronic inflammatory disorder of the airways with variable clinical severity from very mild and occasional symptoms to recurrent critical exacerbations, at risk of fatal or near-fatal outcome, in a small percentage of patients. Within the different inflammatory cascades involved in asthma, eosinophils play a central role in the pathogenesis and largely influence disease severity. Interleukin-5 (IL-5) is the main cytokine controlling eosinophil activity and proliferation at the site of inflammation. Mepolizumab was the first biological humanized anti-IL-5 monoclonal antibody tested in randomized clinical trials on eosinophilic asthma and other eosinophilic diseases. On the basis of several positive clinical efficacy data, it has recently been approved by the US Food and Drug Administration for the treatment of severe eosinophilic asthma. Unfortunately, high costs are at present a critical issue. Future studies will probably help in the correct selection of a potential “responder phenotype”, allowing the prescription of this promising therapy to appropriate patients and best define cost-effectiveness issues.

AB - Asthma is a chronic inflammatory disorder of the airways with variable clinical severity from very mild and occasional symptoms to recurrent critical exacerbations, at risk of fatal or near-fatal outcome, in a small percentage of patients. Within the different inflammatory cascades involved in asthma, eosinophils play a central role in the pathogenesis and largely influence disease severity. Interleukin-5 (IL-5) is the main cytokine controlling eosinophil activity and proliferation at the site of inflammation. Mepolizumab was the first biological humanized anti-IL-5 monoclonal antibody tested in randomized clinical trials on eosinophilic asthma and other eosinophilic diseases. On the basis of several positive clinical efficacy data, it has recently been approved by the US Food and Drug Administration for the treatment of severe eosinophilic asthma. Unfortunately, high costs are at present a critical issue. Future studies will probably help in the correct selection of a potential “responder phenotype”, allowing the prescription of this promising therapy to appropriate patients and best define cost-effectiveness issues.

KW - Asthma

KW - Biomarkers

KW - Effectiveness

KW - IL-5

KW - Mepolizumab

KW - Phenotype

UR - http://www.scopus.com/inward/record.url?scp=84973511460&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84973511460&partnerID=8YFLogxK

U2 - 10.2147/TCRM.S86299

DO - 10.2147/TCRM.S86299

M3 - Review article

AN - SCOPUS:84973511460

VL - 12

SP - 907

EP - 916

JO - Therapeutics and Clinical Risk Management

JF - Therapeutics and Clinical Risk Management

SN - 1176-6336

ER -